Rezŭm water vaporization therapy versus transurethral resection of the prostate in the management of refractory urine retention: matched pair comparative multicenter experience.
Outcomes
Prostate
Rezūm
Transurethral resection
Urine retention
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
08
08
2023
accepted:
15
11
2023
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
20
1
2024
Statut:
epublish
Résumé
To compare the efficacy of Rezūm with a matched cohort of patients undergoing transurethral resection of the prostate (TURP) for catheter-dependent urine retention secondary to benign prostate hyperplasia (BPH). A retrospective review was performed for consecutive catheter-dependent patients who underwent Rezūm for BPH. Patients were matched and compared with a similar cohort undergoing TURP, using non-inferiority analysis on propensity score-matched patient pairs. Patients were followed up at 1, 3, 6 and 12 months by international prostate symptoms score (IPSS), quality of life (QoL) index, peak flow rate (Qmax) and postvoid residual urine (PVR). Eighty-one patients undergoing Rezūm were compared with equal number of matched patients who undergoing TURP. Patients undergoing Rezūm experienced significantly shorter operation time (25.5 ± 8.7 vs. 103.4 ± 12.6 min; p < 0.001), lower intraoperative bleeding (2.4% vs. 20.7%, p < 0.001), shorter hospital stay (1.2 ± 0.9 vs. 2.4 ± 1.3 d, p < 0.001) and longer catheter time (12.6 ± 6.0 vs. 2.3 ± 1.2 d, p < 0.001), with no need for transfusion. Successful postoperative voiding was comparable between both arms (90.2% vs. 92.7%, p = 0.78), respectively. Despite patients undergoing TURP had significantly better voiding outcomes after 1 and 3 months, both groups were comparable after six and 12 months in terms of mean IPSS (11.1 ± 6.4 vs. 10.8 ± 3.4, p = 0.71), QoL indices (2.4 ± 1.6 vs. 2.1 ± 2.3, p = 0.33) and Qmax (22.0 ± 7.7 v. 19.8 ± 6.9 ml/sec, p = 0.06). This study supports the safety and efficacy of Rezūm in the management of catheter-dependent patients secondary to BPH, with comparable functional outcomes to TURP. Until a randomized clinical comparison is available, long-term data are crucially recommended to compare the recurrence and reoperation rates.
Identifiants
pubmed: 38244100
doi: 10.1007/s00345-023-04739-8
pii: 10.1007/s00345-023-04739-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Chan DB, Ross CP, Dubowitch EP et al (2015) Predicting acute urine retention in patients with elevated postvoid residuals. Curr Urol 8(2):79–83. https://doi.org/10.1159/000365694
doi: 10.1159/000365694
Muruganandham K, Dubey D, Kapoor R (2007) Acute urinary retention in benign prostatic hyperplasia: risk factors and current management. Indian J Urol 23(4):347–353. https://doi.org/10.4103/0970-1591.35050
doi: 10.4103/0970-1591.35050
pubmed: 19718286
pmcid: 2721562
Elkoushy MA, Elshal AM, Elhilali MM (2015) Changing patients’ profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: a single-centre perspective. Can Urol Assoc 9(11–12):372–378. https://doi.org/10.5489/cuaj.3066
doi: 10.5489/cuaj.3066
Elshal AM, Elmansy HM, Elhilali MM (2013) Transurethral laser surgery for benign prostate hyperplasia in octogenarians: safety and outcomes. Urology 81(3):634–639. https://doi.org/10.1016/j.urology.2012.11.042
doi: 10.1016/j.urology.2012.11.042
pubmed: 23332997
Rassweiler J, Teber D, Kuntz R (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50:969. https://doi.org/10.1016/j.eururo.2005.12.042
doi: 10.1016/j.eururo.2005.12.042
pubmed: 16469429
Cindolo L, Morselli S, Campobasso D, et al (2023) One-year outcomes after water vapor thermal therapy for symptomatic benign prostatic hyperplasia in an unselected Italian multicenter cohort. Minerva Urol Nephrol 75:203–9. https://doi.org/10.23736/S2724-6051.22.05080-7
Nguyen D-D, Li T, Ferreira R et al (2023) Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: a review of Aquablation, Rezūm, and transperineal laser prostate ablation. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-023-00669-z
doi: 10.1038/s41391-023-00669-z
pubmed: 38114598
pmcid: 10638081
Manfredi C, Arcaniolo D, Spatafora P et al (2022) Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol 74(4):389–399. https://doi.org/10.23736/S2724-6051.21.04530-4
doi: 10.23736/S2724-6051.21.04530-4
pubmed: 34308611
Eredics K, Wehrberger C, Henning A et al (2022) Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency. Prostate Cancer Prostatic Dis 25:302–305. https://doi.org/10.1038/s41391-021-00462-w
doi: 10.1038/s41391-021-00462-w
pubmed: 34588631
McVary KT, Holland B, Beahr JR et al (2020) Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prost Can Prost Dis 23:303–308. https://doi.org/10.1038/s41391-019-0187-5
doi: 10.1038/s41391-019-0187-5
Spinos T, Katafigiotis I, Leotsakos I et al (2023) Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature. World J Urol 41(2):413–420. https://doi.org/10.1007/s00345-022-04258-y
doi: 10.1007/s00345-022-04258-y
pubmed: 36534152
Bassily D, Wong V, Phillips JL et al (2021) Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia. Prostate 81(14):1049–1054. https://doi.org/10.1002/pros.24201
doi: 10.1002/pros.24201
pubmed: 34287992
Garden EB, Devki Shukla D, Ravivarapu KT et al (2021) Rezum therapy for patients with large prostates (≥80 g): initial clinical experience and postoperative outcomes. World J Urol 39:3041–3048. https://doi.org/10.1007/s00345-020-03548-7
doi: 10.1007/s00345-020-03548-7
pubmed: 33392646
pmcid: 7779102
Parsons JK, Dahm P, Köhler TS et al (2020) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2020. J Uro 204(4):799–804. https://doi.org/10.1007/s00345-020-03548-7
doi: 10.1007/s00345-020-03548-7
Mynderse L, Hanson D, Robb R et al (2015) Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 86:122–127. https://doi.org/10.1016/j.urology.2015.03.021
doi: 10.1016/j.urology.2015.03.021
pubmed: 25987496
Dixon C, Cedano E, Mynderse L et al (2015) Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 7:13–18. https://doi.org/10.2147/RRU.S74040
doi: 10.2147/RRU.S74040
pubmed: 25674555
pmcid: 4321608
Tadrist A, Baboudjian M, Bah MB, et al (2023) Water vapor thermal therapy for indwelling urinary catheter removal in frail patients. Int Urol Nephrol 55(2):249–253. https://doi.org/10.1007/s11255-022-03408-w . https://pubmed.ncbi.nlm.nih.gov/36342555/
Siena G, Sessa F, Cindolo L (2023) Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate. Prostate Cancer Prostatic Dis 13:1–3. https://doi.org/10.1038/s41391-023-00644-8
doi: 10.1038/s41391-023-00644-8
Riedinger CB, Fantus RJ, Matulewicz RS (2019) The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. Prostate Cancer Prostatic Dis 22(2):303–308. https://doi.org/10.1038/s41391-018-0104-3
doi: 10.1038/s41391-018-0104-3
pubmed: 30385836
Westwood J, Geraghty R, Jones P et al (2018) Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol 10(11):327–333. https://doi.org/10.1177/1756287218793084
doi: 10.1177/1756287218793084
pubmed: 30344644
pmcid: 6180381
Babar M, Labagnara K, Loloi J et al (2023) Risk factors and real-world short-term outcomes of a failed trial of void after Rezum therapy in a multiethnic population. J Endourol 37(1):67–73. https://doi.org/10.1089/end.2022.0490
doi: 10.1089/end.2022.0490
pubmed: 36029212
Gomes CM, Nunes RV, Araujo RM et al (2008) Urodynamic evaluation of patients with lower urinary tract symptoms and small prostate volume. Urol Int 81(2):129–134. https://doi.org/10.1159/000144049
doi: 10.1159/000144049
pubmed: 18758208